Medigen Vaccine Biologics : Resolution to issue new shares for capital increase through profits by Board of Directors

Close

Today's Information

Provided by: Medigen Vaccine Biologics Corporation
SEQ_NO	3	Date of announcement	2022/03/01	Time of announcement	16:14:17
Subject	Resolution to issue new shares for capital increase through profits by Board of Directors
Date of events	2022/03/01	To which item it meets	paragraph 11
Statement	1.Date of the board of directors resolution:2022/03/01 2.Source of capital increase funds:2021 profits 3.Whether to adopt shelf registration (Yes, please state issuance period/No):No 4.Total monetary value of the issuance and number of shares issued (shares issued not including those distributed to employees if consisting in capital increase from earnings or capital surplus): Total monetary value of the issuance：NTD 1,067,195,500 Number of shares issued：106,719,550 shares 5.If adopting shelf registration, monetary value and number of shares to be issued this time:N/A 6.The remaining monetary value and shares after this issuance when adopting shelf registration:N/A 7.Par value per share:NTD 10 8.Issue price:N/A 9.Number of shares subscribed for by or allocated to employees:N/A 10.Number of shares publicly sold:N/A 11.Ratio of shares subscribed by or allotted as stock dividends to existing shareholders: Receive 500 shares for each 1,000 shares. 12.Handling method for fractional shares and shares unsubscripted for by the deadline: If there are less than 1 share of abnormal shares allotted, the shareholders shall make up their own shares within 5 days from the date of closing the transfer of accounts. If there is still less than 1 share after making up or the share has not been made up within the time limit, the denomination will be converted into cash and calculated up to NTD (all below NTD are rounded up),Then authorize the chairman to negotiate with a specific person to purchase at face value. 13.Rights and obligations of these newly issued shares: The rights and obligations of this capital increase are the same as those of the existing issued common shares. 14.Utilization of the funds from the capital increase: Enrichment of working capital 15.Any other matters that need to be specified: (1)The rights and obligations of insubstantial shares in this capital increase are the same as those of the original shares. After being approved by the regular shareholders' meeting and submitted to the competent authority for approval, the board of directors is authorized to determine the ex-rights allotment base date, distribution date and other related matters. (2)If the company subsequently repurchases the company's shares to carry out the transfer or cancellation of treasury shares, or the conversion of domestic convertible corporate bonds, which affects the number of shares in circulation and the shareholders' allotment rate changes as a result, it is proposed to request the shareholders' meeting to authorize the chairman of the board.Handle changes related matters. (3)If the above-mentioned matters related to capital increase and issuance of new shares need to be amended due to the regulations of the competent authority or the objective environmental impact, it is proposed to submit to the shareholders' meeting to authorize the chairman to handle them with full authority.